R&D News | pharmaphorum

News

Merck, Moderna cue up phase 3 trials for mRNA cancer shot

Moderna and partner Merck & Co have fleshed out the data from their clinical trial of personalised mRNA vaccine for melanoma, saying the results support the start of a

News

Biomarker hailed as “game changer” in Parkinson’s

Researchers have discovered a new biomarker for Parkinson’s that could be used to identify people at risk of the disease and profoundly change the way it is treated.

News

Merck fires up a $10.8bn Prometheus takeover bid

Merck & Co has reached an agreement to buy Prometheus Biosciences in a $200-per-share cash transaction that values the San Diego-based biotech at $10.8 billion.

News

Prothena taps Walgreens network for Alzheimer’s trial

Walgreens' move into the clinical trials category has earned it a deal with biotech company Prothena, which will use its network of community pharmacies to identify and re

News

Acelyrin files IPO – is a biotech comeback on the way?

Initial public offerings in the biotech sector nosedived last year after a lot of activity in 2021, but have remained few and far between this year amid tough economic con

News

More claudin buzz as Alentis raises $105m

Swiss biotech Alentis Therapeutics has raised a very respectable $105 million in third-round financing that will be dedicated to the development of its Claudin-targeting d

Merck, Moderna cue up phase 3 trials for mRNA cancer shot

Biomarker hailed as “game changer” in Parkinson’s

Merck fires up a $10.8bn Prometheus takeover bid

Prothena taps Walgreens network for Alzheimer’s trial

Acelyrin files IPO – is a biotech comeback on the way?

More claudin buzz as Alentis raises $105m

Chiesi signs $1.9bn deal to buy KalVista and its HAE drug

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks